Pharmacokinetic properties of hydroxysafflor yellow A in healthy Chinese female volunteers

被引:40
作者
Yang, Zhifu [1 ]
Yang, Jing [1 ]
Jia, Yanyan [1 ]
Tian, Yun [1 ]
Wen, Aidong [1 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp, Dept Pharm, Xian 710032, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Hydroxysafflor yellow A; Safflor yellow; Safflower; Pharmacokinetic; SAFFLOWER; RATS;
D O I
10.1016/j.jep.2009.02.026
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Hydroxysafflor yellow A (HSYA) was isolated from the dried flower of Carthamus tinctorius L. which was extensively used in traditional Chinese medicine to treat diseases due to blood stasis. However, there have been few detailed pharmacokinetic studies about HSYA on human beings. Aim of the study: The aim was to investigate the pharmacokinetic characteristics of HSYA in healthy Chinese female volunteers. Materials and methods: The volunteers were given intravenous infusion of single doses of safflor yellow injection (containing HSYA 35, 70 and 140 mg) in separate trial periods with 1 week washout period. The concentration levels of HSYA in plasma were determined with HPLC. Various pharmacokinetic parameters were estimated from the plasma concentration versus time data using non-compartmental methods. Results: The C-max values were 2.02 +/- 0.18, 7.47 +/- 0.67 and 14.48 +/- 4.71 mu g/ml. after the administration of single doses of 35, 70, and 140 mg of HSYA, respectively. The corresponding values of AUC(0-15h) were 6.57 +/- 1.20, 25.90 +/- 4.62 and 48.47 +/- 12.11 mu g/(mL h(-1)), and the values of t(1/2) were 3.21 +/- 1.26, 3.33 +/- 0.68 and 2.98 +/- 0.09 h. The Student-Newman-Keuls test results showed that C-max and AUC(0-15h) were both linearly related to dose. Conclusions: In this study, the pharmacokinetic properties of HSYA are based on first-order kinetics over the dose range tested. (C) 2009 Published by Elsevier Ireland Ltd.
引用
收藏
页码:635 / 638
页数:4
相关论文
共 20 条
[1]   Pharmacokinetics and excretion of hydroxysafflor Yellow A, a potent neuroprotective agent from safflower, in rats and dogs [J].
Chu, DF ;
Liu, WH ;
Huang, Z ;
Liu, SS ;
Fu, XQ ;
Liu, K .
PLANTA MEDICA, 2006, 72 (05) :418-423
[2]  
*EUR AG EV MED PRO, 2005, INT C HARM WHO GUID
[3]   RETRACTED: Protective effects of hydroxysafflor yellow A on acute and chronic congestive cardiac failure mediated by reducing ET-1, NOS and oxidative stress in rats (Retracted article. See vol. 61, pg. 685, 2009) [J].
He, Haibo ;
Yang, Xianzhe ;
Shi, Mengqiong ;
Zeng, Xiaowei ;
Yang, Jun ;
Wu, Limao ;
Li, Lianda .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2008, 60 (01) :115-123
[4]  
Jin Ming, 2004, Zhongguo Zhong Yao Za Zhi, V29, P447
[5]  
KOHEI K, 2000, BIOSCI BIOTECH BIOCH, V64, P1588
[6]  
Li Yanmei, 1998, Yaoxue Xuebao, V33, P626
[7]   Determination of hydroxysafflor yellow A in rat plasma and tissues by high-performance liquid chromatography after oral administration of safflower extract or safflor yellow [J].
Li, Yi ;
Zhang, Zhao-yang ;
Zhang, Jin-lan .
BIOMEDICAL CHROMATOGRAPHY, 2007, 21 (03) :326-334
[8]  
LIANG W, 2002, BIOPHARMACEUCTICS PH, P241
[9]  
Liang X.T., 2004, BASIC STUDY COMMON 2, P102
[10]  
Liu F., 1992, Acta Pharmaceutica Sinica, V27, P785